Regenity Biosciences

Founded in 1997 and headquartered in New Jersey, USA, Regenity has spent nearly 30 years advancing innovative biomaterials that support the body’s natural healing processes for tissue and bone regeneration across multiple clinical areas, including dental, orthopaedic, spine, neurosurgery, advanced wound, sports medicine, ENT, and nerve repair. Today, the Company’s team of over 250 employees serves more than 125 customers with 80+ product lines globally.

Regenity has an established history of product development and manufacturing, demonstrated by a broad portfolio of FDA-approved solutions and over 100 patents, with more than 5 million patients treated in 2025 and over 30 million patients treated since its founding. Its scientific approach combines proprietary materials science, deep technical experience, and a commitment to making a material difference in patient outcomes by taking breakthrough solutions from rapid prototyping to commercial reality.